ResMed Inc

Insider selling 2,000 ResMed shares under a Rule 10b‑5 plan shows disciplined liquidity management, not a warning—steady prices, modest impact, and solid fundamentals.

ResMed CFO Brett Sandercock sells 1,000 shares at $257.03 under a Rule 10b‑5‑1 plan, sparking modest market reaction and prompting investors to monitor insider‑trading patterns amid solid earnings and steady fundamentals.